Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Share-based compensation expense related to employee stock plans

Share-based compensation expense related to employee stock plans at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
——
Zymeworks logo
ZymeworksZYME
——
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
——

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's share-based compensation expense related to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's share-based compensation expense related to employee stock plans?
BioCryst Pharmaceuticals (BCRX) reported share-based compensation expense related to employee stock plans of $16.03M in Q1 2026.
How has BioCryst Pharmaceuticals's share-based compensation expense related to employee stock plans changed year-over-year?
BioCryst Pharmaceuticals's share-based compensation expense related to employee stock plans decreased by 25.0% year-over-year, from $21.37M to $16.03M.
What is the long-term trend for BioCryst Pharmaceuticals's share-based compensation expense related to employee stock plans?
Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's share-based compensation expense related to employee stock plans has grown at a 25.2% compound annual growth rate (CAGR), from $34.64M to $85.14M.